TAS2R45 Antibody

What is TAS2R45 and what is its primary biological function?

TAS2R45 (Taste Receptor Type 2 Member 45) is a G-protein coupled receptor that belongs to the T2R family of bitter taste receptors. Its primary function appears to be in the perception of bitterness and is gustducin-linked. Beyond taste perception, TAS2R45 may play roles in sensing the chemical composition of gastrointestinal contents . The receptor's activity can stimulate alpha gustducin, mediate PLC-beta-2 activation, and lead to the gating of TRPM5 .

Research has shown that TAS2R45 and other T2Rs are expressed not only in taste buds but also in various extraoral tissues, suggesting functions beyond taste perception. The full sequence of human TAS2R45 protein consists of 299 amino acids, and the protein typically localizes to cellular membranes as a multi-pass membrane protein .

How is TAS2R45 expression distributed across different human tissues?

TAS2R45 shows variable expression across human tissues. Studies have detected TAS2R45 expression in:

• Head and neck squamous cell carcinoma (HNSCC) tissues and cell lines

• Human skin tissues, with expression levels potentially influenced by sun exposure

In HNSCC cell lines (SCC4, SCC15, SCC47, SCC90, SCC152, OCTT2, and VU147T), TAS2R45 is among the consistently highly expressed T2R receptors . In human skin samples analyzed through the GTEx project, TAS2R45 shows variable expression among the 25 TAS2R genes studied, with some individuals showing expression while others do not .

What is the current understanding of TAS2R45's potential role in disease pathogenesis?

Recent research suggests potential roles for bitter taste receptors, including TAS2R45, in cancer biology. Studies on head and neck squamous cell carcinoma (HNSCC) indicate that T2Rs may regulate apoptosis and could be associated with cancer progression and patient outcomes .

While the specific role of TAS2R45 in disease pathogenesis is still being elucidated, research suggests these receptors might be important for risk stratification in HNSCC and potentially represent novel therapeutic targets . The differential expression patterns observed in cancer versus normal tissues warrant further investigation with larger patient populations to determine specific associations with clinical outcomes.

What criteria should be considered when selecting a TAS2R45 antibody for research?

When selecting a TAS2R45 antibody for research, consider these key factors:

• Target epitope region: Different antibodies target different regions of the TAS2R45 protein. For example, available antibodies target amino acid regions 211-260, 181-230, or 221-270 . The choice should align with your experimental goals, especially if you're interested in specific domains of the protein.

• Host species and clonality: Most available TAS2R45 antibodies are rabbit polyclonal antibodies , which may provide good sensitivity but potentially less specificity than monoclonal options.

• Validated applications: Ensure the antibody is validated for your intended application. Available TAS2R45 antibodies are typically validated for:

  • Western Blotting (WB)

  • ELISA

  • Immunocytochemistry (ICC)

  • Immunofluorescence (IF)

• Species reactivity: Confirm that the antibody reacts with your species of interest. Some antibodies recognize only human TAS2R45, while others cross-react with rat/mouse or other species .

• Specificity documentation: Review available data showing the antibody detects endogenous levels of TAS2R45 protein with minimal cross-reactivity to other proteins.

How can researchers validate the specificity of a TAS2R45 antibody?

To validate the specificity of a TAS2R45 antibody:

• Positive and negative controls: Use tissues or cell lines known to express TAS2R45 (such as SCC47 or SCC4 cell lines ) as positive controls. As negative controls, use tissues or cell lines where TAS2R45 is not expressed or use siRNA knockdown of TAS2R45.

• Multiple detection methods: Confirm TAS2R45 detection using at least two independent methods (e.g., Western blotting and immunofluorescence) to ensure consistent results.

• Epitope competition assay: Pre-incubate the antibody with the immunizing peptide before staining to confirm that this blocks specific binding.

• Molecular weight verification: In Western blots, confirm that the detected band corresponds to the expected molecular weight of TAS2R45.

• Subcellular localization assessment: Use confocal microscopy to confirm that the antibody detects TAS2R45 in expected cellular compartments (primarily membrane-bound, though some T2Rs have been observed in intracellular compartments) .

What are the optimal protocols for using TAS2R45 antibodies in Western blotting experiments?

For optimal Western blotting with TAS2R45 antibodies:

• Sample preparation:

  • Extract total protein from your sample of interest

  • Include appropriate positive controls (e.g., HNSCC cell lines with known TAS2R45 expression )

  • Denature proteins in loading buffer containing SDS and β-mercaptoethanol

• Gel electrophoresis and transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Antibody incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Dilute primary TAS2R45 antibody at 1:500-1:2000 as recommended by manufacturers

  • Incubate overnight at 4°C

  • Wash thoroughly with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody

• Detection and analysis:

  • Develop using ECL reagents

  • Expected molecular weight for human TAS2R45 is approximately 36 kDa

  • Include loading controls (β-actin, GAPDH, etc.)

• Data interpretation:

  • Quantify band intensity using appropriate software

  • Normalize to loading controls for comparative analysis

How can researchers effectively use TAS2R45 antibodies for immunofluorescence studies?

For effective immunofluorescence studies with TAS2R45 antibodies:

• Sample preparation:

  • For cultured cells: Grow cells on coverslips, fix with 4% paraformaldehyde, and permeabilize with 0.1-0.2% Triton X-100

  • For tissue sections: Use freshly frozen or FFPE sections with appropriate antigen retrieval if needed

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from the species of the secondary antibody

  • Dilute TAS2R45 primary antibody at 1:100-1:500 as recommended

  • Incubate overnight at 4°C in a humidified chamber

  • Wash thoroughly with PBS

• Secondary antibody and counterstaining:

  • Use fluorophore-conjugated secondary antibodies specific to the host species of the primary antibody

  • Include nuclear counterstain (DAPI or Hoechst)

  • Consider co-staining with markers of relevant cellular compartments

• Imaging and analysis:

  • Use confocal microscopy for detailed subcellular localization

  • Consider that TAS2R45, like other T2Rs, may localize to both plasma membrane and intracellular compartments

  • Include appropriate controls to distinguish specific from non-specific staining

• Interpretation considerations:

  • Compare observed localization patterns with published data

  • Note that T2Rs can show variable localization patterns in different cell types

What approaches can be used to study TAS2R45 expression at the mRNA level?

For studying TAS2R45 expression at the mRNA level:

• RNA extraction and quality assessment:

  • Extract total RNA using standard methods

  • Verify RNA integrity by gel electrophoresis or Bioanalyzer

  • Treat with DNase to remove genomic DNA contamination

• RT-PCR/qPCR approach:

  • Design specific primers for TAS2R45 (consider potential homology with other TAS2R family members)

  • Use appropriate housekeeping genes for normalization

  • Include genomic DNA controls to verify specificity

  • Consider the potential low abundance of TAS2R45 transcripts when designing experiments

• RNA-Seq analysis:

  • RNA-Seq provides more accurate detection of low-abundance transcripts

  • Analyze data in RPKM units (reads per kilobase of transcript per million mapped reads)

  • Compare TAS2R45 expression across different tissues or experimental conditions

• Controls and validation:

  • Include positive controls with known TAS2R45 expression

  • Validate key findings with multiple methods (e.g., qPCR and RNA-Seq)

  • Consider technical replicates to account for variability in low-abundance transcripts

How can researchers investigate the potential role of TAS2R45 in cancer biology?

To investigate TAS2R45's potential role in cancer biology:

• Expression analysis in patient samples:

  • Compare TAS2R45 expression in tumor vs. matched normal tissues using qPCR, Western blotting, or immunohistochemistry

  • Correlate expression levels with clinical parameters and patient outcomes

  • Consider analyzing larger patient populations to identify statistically significant patterns

• Functional studies in cancer cell lines:

  • Use siRNA or CRISPR-Cas9 to knock down/out TAS2R45 expression

  • Assess effects on cancer cell phenotypes:

    • Proliferation rates

    • Apoptosis markers

    • Migration and invasion capabilities

    • Response to chemotherapeutic agents

• Signaling pathway analysis:

  • Investigate how TAS2R45 activation or inhibition affects known cancer-related signaling pathways

  • Consider the connection to gustducin, PLC-beta-2, and TRPM5 pathways

  • Examine potential cross-talk with other cancer-relevant pathways

• In vivo models:

  • Develop xenograft models with TAS2R45-modulated cancer cells

  • Assess tumor growth, metastasis, and response to treatments

• Potential as therapeutic target:

  • Screen for specific agonists or antagonists of TAS2R45

  • Evaluate their effects on cancer cell growth and survival

  • Assess potential for combination therapies

What methodologies can be employed to study TAS2R45 protein-protein interactions?

To study TAS2R45 protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use TAS2R45 antibodies to pull down the receptor and associated proteins

  • Analyze co-precipitated proteins by mass spectrometry or Western blotting

  • Validate interactions with reverse Co-IP

• Proximity ligation assay (PLA):

  • Use antibodies against TAS2R45 and potential interacting proteins

  • Visualize and quantify protein-protein interactions in situ

• Bimolecular fluorescence complementation (BiFC):

  • Create fusion constructs of TAS2R45 and potential interacting proteins with split fluorescent protein fragments

  • Assess interaction through reconstitution of fluorescence

• FRET/BRET approaches:

  • Generate fluorescent or bioluminescent fusion proteins

  • Monitor resonance energy transfer as indication of protein proximity

• Yeast two-hybrid or mammalian two-hybrid screening:

  • Identify novel interaction partners using TAS2R45 as bait

  • Validate findings with orthogonal methods

• Cross-linking mass spectrometry:

  • Use chemical cross-linkers to capture transient interactions

  • Identify interacting proteins and interaction sites by mass spectrometry

How can researchers investigate differential expression of TAS2R45 under varying physiological conditions?

To investigate differential expression of TAS2R45 under varying conditions:

• Tissue-specific expression analysis:

  • Compare TAS2R45 expression across multiple tissues using qPCR, Western blotting, or immunohistochemistry

  • Analyze existing RNA-Seq databases like GTEx for tissue-specific expression patterns

  • Consider potential differences related to factors such as sun exposure in skin samples

• Cell culture models for environmental factors:

  • Expose relevant cell lines to various stimuli:

    • Inflammatory mediators

    • Growth factors

    • Hypoxia

    • UV radiation (particularly for skin cells)

  • Monitor changes in TAS2R45 expression at mRNA and protein levels

• Demographic and physiological variables:

  • Analyze expression data stratified by:

    • Age

    • Sex (as some T2Rs show sex-specific expression patterns)

    • Disease state

  • Use statistical approaches to identify significant correlations

• Epigenetic regulation:

  • Investigate DNA methylation status of the TAS2R45 promoter under different conditions

  • Analyze histone modifications associated with TAS2R45 gene regulation

  • Consider the role of non-coding RNAs in post-transcriptional regulation

• Temporal analysis:

  • Study changes in TAS2R45 expression over time:

    • During development

    • In response to stimuli

    • In disease progression

What are common challenges when working with TAS2R45 antibodies and how can they be addressed?

Common challenges and solutions when working with TAS2R45 antibodies:

• Low signal intensity:

  • Problem: T2Rs, including TAS2R45, are often expressed at low levels

  • Solutions:

    • Increase antibody concentration (within manufacturer's recommended range)

    • Extend incubation time

    • Use signal amplification methods (e.g., TSA)

    • Enrich for membrane fractions when possible

• Non-specific binding:

  • Problem: Cross-reactivity with related T2R family members

  • Solutions:

    • Use more stringent blocking conditions

    • Validate with peptide competition assays

    • Consider antibodies targeting less conserved regions of TAS2R45

    • Include appropriate negative controls

• Inconsistent results between experiments:

  • Problem: Variable expression or technical variations

  • Solutions:

    • Include positive controls consistently

    • Standardize protocols meticulously

    • Use multiple technical replicates

    • Consider using recombinant TAS2R45 protein as a standard

• Discrepancies between mRNA and protein expression:

  • Problem: Post-transcriptional regulation affecting correlation

  • Solutions:

    • Analyze both mRNA and protein levels in parallel

    • Consider time-course experiments to account for temporal differences

    • Investigate potential regulatory mechanisms

• Challenges with membrane protein extraction:

  • Problem: TAS2R45 is a multi-pass membrane protein

  • Solutions:

    • Use detergent-based extraction methods optimized for membrane proteins

    • Consider native extraction conditions when protein folding is important

    • Avoid excessive heating which may cause aggregation

How should researchers interpret variability in TAS2R45 expression between samples?

When interpreting variability in TAS2R45 expression:

• Biological versus technical variability:

  • Determine whether variability reflects true biological differences or technical limitations

  • Include technical replicates to assess reproducibility

  • Consider the inherently low abundance of T2R transcripts which may increase technical variability

• Individual variation factors:

  • Consider potential influences on expression:

    • Genetic polymorphisms in TAS2R45 gene

    • Age-related changes in expression

    • Sex differences (observed for some T2Rs)

    • Environmental exposures (e.g., sun exposure in skin)

• Tissue heterogeneity considerations:

  • Assess whether differences in cellular composition could explain variability

  • Consider using single-cell approaches for heterogeneous tissues

  • Use laser capture microdissection to isolate specific cell populations

• Quantification methods:

  • Use appropriate normalization strategies:

    • For qPCR: Validate reference genes in your specific experimental context

    • For Western blot: Normalize to loading controls and consider total protein normalization

    • For immunohistochemistry: Use standardized scoring systems

• Statistical approaches:

  • Apply appropriate statistical tests based on data distribution

  • Consider non-parametric tests for highly variable data

  • Use larger sample sizes to better characterize expression patterns